• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

非小细胞肺癌侵犯肺裂的外科处理:少即是多?

Surgical Management of Non-Small Cell Lung Cancer Invading the Fissure: Less Is More?

机构信息

Division of Thoracic Surgery, Swedish Medical Center and Cancer Institute, Seattle, Washington.

Division of Thoracic Surgery, Swedish Medical Center and Cancer Institute, Seattle, Washington.

出版信息

Ann Thorac Surg. 2021 Jan;111(1):231-236. doi: 10.1016/j.athoracsur.2020.05.082. Epub 2020 Jul 9.

DOI:10.1016/j.athoracsur.2020.05.082
PMID:32653363
Abstract

BACKGROUND

When a resectable lung cancer that invades across the fissure into an adjacent lobe is encountered, options include a bilobectomy on the right or a pneumonectomy on the left vs a parenchymal-sparing resection combined with a lobectomy. Although parenchymal-sparing combinations are technically possible, the available literature reporting on the related oncologic outcomes is limited. We sought to examine the influence of resection extent on overall survival and recurrence patterns in this scenario.

METHODS

A single-center retrospective medical record review from 2006 to 2018 was performed on all preoperative computed tomography and operative reports of resections greater than a lobectomy. Patients were grouped into maximal resection: bilobectomy or pneumonectomy, and parenchymal-sparing resection: lobectomy with en bloc segment or nonanatomic wedge. Overall survival and cumulative incidence of recurrence were calculated.

RESULTS

The size of our cohort was 54 patients; 19 maximal and 35 parenchymal-sparing resections. All resections were reported as complete (R0). The parenchymal-sparing group had lower odds of immediate surgical morbidity (odds ratio, 0.13; 95% confidence interval, 0.02-0.74; P = .02). Parenchymal-sparing resection was not associated with an increased cumulative incidence of recurrence (P = .98). Postresection estimated overall survival between the 2 cohorts was not significantly different (P = .30).

CONCLUSIONS

When technically feasible, a parenchymal-sparing resection is a good option for the resection of tumors that invade across the fissure. R0 parenchymal-sparing resections do not appear to compromise the oncologic outcomes of overall survival or cumulative incidence of recurrence and also seem to carry less morbidity.

摘要

背景

当遇到可切除的肺癌侵犯裂并延伸至相邻肺叶时,可选择行右侧全肺切除术或左侧肺叶切除术,也可选择行保留肺实质的肺段切除术联合肺叶切除术。虽然保留肺实质的联合切除术在技术上是可行的,但相关的肿瘤学结果的文献报道有限。我们旨在研究在此情况下,切除范围对总生存率和复发模式的影响。

方法

对 2006 年至 2018 年所有大于肺叶切除术的术前 CT 和手术报告进行了单中心回顾性病历审查。患者被分为最大程度的切除术组:全肺切除术或肺叶切除术,以及保留肺实质的切除术组:肺叶切除术联合整块肺段切除术或非解剖楔形切除术。计算总生存率和复发的累积发生率。

结果

我们的队列大小为 54 例患者;19 例最大程度的切除术和 35 例保留肺实质的切除术。所有切除均报告为完全切除(R0)。保留肺实质的组的即时手术发病率较低(优势比,0.13;95%置信区间,0.02-0.74;P =.02)。保留肺实质的切除术与复发的累积发生率增加无关(P =.98)。两组之间的术后估计总生存率无显著差异(P =.30)。

结论

在技术上可行的情况下,对于侵犯裂的肿瘤,保留肺实质的切除术是一种很好的选择。R0 保留肺实质的切除术似乎不会影响总生存率或复发的累积发生率的肿瘤学结果,而且似乎发病率也较低。

相似文献

1
Surgical Management of Non-Small Cell Lung Cancer Invading the Fissure: Less Is More?非小细胞肺癌侵犯肺裂的外科处理:少即是多?
Ann Thorac Surg. 2021 Jan;111(1):231-236. doi: 10.1016/j.athoracsur.2020.05.082. Epub 2020 Jul 9.
2
Oncological Outcomes of Lobar Resection, Segmentectomy, and Wedge Resection for T1a Non-Small-Cell Lung Carcinoma: A Systematic Review and Meta-Analysis.T1a 期非小细胞肺癌行肺叶切除术、节段切除术和楔形切除术的肿瘤学结果:系统评价和荟萃分析。
Semin Thorac Cardiovasc Surg. 2020;32(3):582-590. doi: 10.1053/j.semtcvs.2019.08.004. Epub 2019 Aug 9.
3
Staging and resection of lung cancer with minimal invasion of the adjacent lobe.肺癌的分期及对相邻肺叶侵袭最小的切除术。
Eur J Cardiothorac Surg. 2007 Dec;32(6):855-8. doi: 10.1016/j.ejcts.2007.09.017. Epub 2007 Nov 1.
4
Adjacent lobe invasion of T2 tumor in non-small cell lung cancer has T3 disease-like survival fissure invasion: T2 or T3?非小细胞肺癌中T2肿瘤的相邻肺叶侵犯具有类似T3期疾病的脏层胸膜侵犯:T2还是T3?
Updates Surg. 2023 Oct;75(7):2017-2025. doi: 10.1007/s13304-023-01616-2. Epub 2023 Aug 10.
5
Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer.非小细胞肺癌袖状肺叶切除术后的发病率、死亡率和长期生存率
Eur J Cardiothorac Surg. 2007 Jan;31(1):95-102. doi: 10.1016/j.ejcts.2006.10.031. Epub 2006 Nov 28.
6
Margin Distance Does Not Influence Recurrence and Survival After Wedge Resection for Lung Cancer.切缘距离不影响肺癌楔形切除术后的复发及生存情况。
Ann Thorac Surg. 2015 Sep;100(3):918-24; discussion 924-5. doi: 10.1016/j.athoracsur.2015.04.064. Epub 2015 Jul 21.
7
Long-Term Results for Clinical Stage IA Lung Cancer: Comparing Lobectomy and Sublobar Resection.临床ⅠA 期肺癌的长期结果:肺叶切除术与亚肺叶切除术比较。
Ann Thorac Surg. 2018 Aug;106(2):375-381. doi: 10.1016/j.athoracsur.2018.02.049. Epub 2018 Mar 23.
8
Long-term outcomes of en bloc resection of non-small cell lung cancer invading the thoracic inlet and spine.胸入口和脊柱受侵非小细胞肺癌整块切除术的长期疗效。
Ann Thorac Surg. 2011 Sep;92(3):1024-30; discussion 1030. doi: 10.1016/j.athoracsur.2011.04.100.
9
Wedge resection versus lobectomy for stage I (T1 N0 M0) non-small-cell lung cancer.I期(T1 N0 M0)非小细胞肺癌的楔形切除术与肺叶切除术对比
J Thorac Cardiovasc Surg. 1997 Apr;113(4):691-8; discussion 698-700. doi: 10.1016/S0022-5223(97)70226-5.
10
Surgical treatment in patient with non-small-cell lung cancer with fissure involvement: anatomical versus nonanatomical resection.非小细胞肺癌伴裂隙累及患者的外科治疗:解剖性与非解剖性切除。
J Thorac Oncol. 2014 Jan;9(1):97-108. doi: 10.1097/JTO.0000000000000040.

引用本文的文献

1
Thoracoscopic anatomical sublobar resection for deep interlobar lung cancer with fused fissure.胸腔镜下解剖性亚肺叶切除术治疗伴有融合性肺裂的深部叶间肺癌
J Thorac Dis. 2024 Dec 31;16(12):8162-8172. doi: 10.21037/jtd-24-84. Epub 2024 Dec 28.
2
Adjacent lobe invasion of T2 tumor in non-small cell lung cancer has T3 disease-like survival fissure invasion: T2 or T3?非小细胞肺癌中T2肿瘤的相邻肺叶侵犯具有类似T3期疾病的脏层胸膜侵犯:T2还是T3?
Updates Surg. 2023 Oct;75(7):2017-2025. doi: 10.1007/s13304-023-01616-2. Epub 2023 Aug 10.
3
TRIM17-mediated ubiquitination and degradation of RBM38 promotes cisplatin resistance in non-small cell lung cancer.
TRIM17介导的RBM38泛素化和降解促进非小细胞肺癌的顺铂耐药。
Cell Oncol (Dordr). 2023 Oct;46(5):1493-1507. doi: 10.1007/s13402-023-00825-6. Epub 2023 May 23.
4
A Retrospective Study of Effectiveness of Thoracoscopic Lobectomy and Segmentectomy in Patients with Early-Stage Non-Small-Cell Lung Cancer.一项回顾性研究:胸腔镜肺叶切除术和节段切除术治疗早期非小细胞肺癌的疗效。
Dis Markers. 2022 Apr 28;2022:6975236. doi: 10.1155/2022/6975236. eCollection 2022.